20 terminated. 20 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Terminated 20 |
| Phase 2 | 1 | Terminated 1 |
Follow Sickle Cell Disease: new trials by email Literature Review of Sickle Cell Disease trials Research Report on Sickle Cell Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) Osivelotor - Sickle Cell Disease | Phase 2 / Phase 3 | Terminated | Pfizer | 47 | 2023-01-05 | 2026-03-19 |
| Voxelotor Neurocognitive Function Study Voxelotor Only Product in Oral Dose Form, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 1 | 2022-06-24 | 2024-05-02 |
| THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) Rivaroxaban 10 MG, Placebo - Sickle Cell Disease, Central Venous Catheter Thrombosis | Phase 3 | Terminated | University Health Network, Toronto | 4 | 2022-06-07 | 2025-03-19 |
| Resolution of Sickle Cell Leg Ulcers With Voxelotor Voxelotor Oral Tablet, Placebo - Sickle Cell Disease, Leg Ulcers | Phase 3 | Terminated | Pfizer | 88 | 2022-05-30 | 2025-07-09 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 242 | 2022-03-29 | 2025-12-17 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 72 | 2021-12-09 | 2024-12-11 |
| Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease Voxelotor, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 236 | 2020-11-11 | 2026-03-10 |
| Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED Intranasal ketamine - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Terminated | Abigail Nixon | 5 | 2019-12-19 | 2024-11-18 |
| Open-Label Extension of Voxelotor Voxelotor - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 162 | 2019-11-18 | 2025-11-13 |
| Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease Patient-Specific Protocol, Weight-based Protocol, Morphine - Sickle Cell Disease | Phase 3 | Terminated | Duke University | 328 | 2019-08-13 | 2023-07-03 |
| Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Ticagrelor, Placebo - Sickle Cell Disease | Phase 3 | Terminated | AstraZeneca | 193 | 2018-09-26 | 2021-04-09 |
| Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 Voxelotor - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 179 | 2018-06-06 | 2025-11-18 |
| Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease Rivipansel - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Terminated | GlycoMimetics Incorporated | 154 | 2015-12-16 | 2021-02-10 |
| Apixaban in Patients With Sickle Cell Disease Apixaban, Placebo - Vaso-occlusive Crisis, Reduction in Hospitalizations | Phase 3 | Terminated | Nirmish Shah | 16 | 2015-01-01 | 2020-03-11 |
| A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD) Prasugrel, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Eli Lilly and Company | 341 | 2013-04-01 | 2019-09-25 |
| THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA) High Demand / Low Infusion, PCA Dosing Plan - Sickle Cell Disease | Phase 3 | Terminated | Carelon Research | 38 | 2010-01-01 | 2013-04-18 |
| Transfusion Alternatives Pre-operatively in Sickle Cell Disease (TAPS) Red blood cell transfusion - Sickle Cell Disease | Phase 3 | Terminated | NHS Blood and Transplant | 70 | 2007-07-01 | 2023-03-23 |
| A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy ICA-17043 - Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Terminated | Icagen | 51 | 2006-02-01 | 2007-09-11 |
| Steroid Treatment for Sickle Cell Pain Crisis Steroid arm, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Baylor College of Medicine | 18 | 2005-12-01 | 2020-07-07 |
| A Stratified Sickle Event Randomized Trial (ASSERT) ICA-17043 - Sickle Cell Disease | Phase 3 | Terminated | Icagen | 297 | 2005-02-01 | 2008-03-27 |
Anemia, Sickle Cell (20) · Vaso-Occlusive Crises (7) · Hematologic Diseases (2) · Agnosia (1) · Leg Ulcer (1) · Sickle Cell Trait (1) · Upper Extremity Deep Vein Thrombosis (1) · Venous Thromboembolism (1)
Anemia (20) · Anemia, Hemolytic (20) · Anemia, Hemolytic, Congenital (20) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20) · Genetic Diseases, Inborn (20) · Hemic and Lymphatic Diseases (20) · Hemoglobinopathies (20) · Hematologic Diseases (18) · Cardiovascular Diseases (1) · Embolism and Thrombosis (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Perceptual Disorders (1)
voxelotor (4) · inclacumab (2) · senicapoc (2) · Dosage Forms (1) · Erythrocyte Transfusion (1) · Hydromorphone (1) · Morphine (1) · Prasugrel Hydrochloride (1) · Rivaroxaban (1) · Ticagrelor (1) · apixaban (1) · rivipansel (1)
Pfizer (8) · Icagen (2) · Abigail Nixon (1) · AstraZeneca (1) · Baylor College of Medicine (1) · Carelon Research (1) · Duke University (1) · Eli Lilly and Company (1) · GlycoMimetics Incorporated (1) · NHS Blood and Transplant (1) · Nirmish Shah (1) · University Health Network, Toronto (1)
United States (17) · United Kingdom (8) · Kenya (7) · Brazil (6) · Lebanon (6) · Nigeria (6) · Egypt (5) · Italy (5) · Oman (5) · Turkey (Türkiye) (5) · Canada (4) · Saudi Arabia (4) · France (3) · Ghana (3) · Belgium (2)
Anders Berggren, MD, PhD (1) · Carlton Dampier, MD (1) · Huiman Barnhart, PhD (1) · Jonathan W Stocker, Ph.D. (1) · Jonathan W Stocker, PhD (1) · Lorna M Williamson, MRCP,MRCPath (1) · Matthew Heeney, MD (1) · Nirmish Shah, MD (1) · Sally C Davies, MRCP,MRCPath (1) · Wally Smith, MD (1)
PMID 23539110, PMID 26644172, PMID 31446143, PMID 35849650, PMID 35981565, PMID 38171625, PMID 39154808, PMID 41249873, PMID 42665434
2019 (2), 2017 (1), U10HL083721 (1), U24HL137907 (1)